NCT01520246

Brief Summary

RATIONALE: Studying samples of blood and tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer. It may also help doctors find better ways to treat cancer. PURPOSE: This research trial studies gene expression in samples from patients with T-cell acute lymphoblastic leukemia.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
20

participants targeted

Target at below P25 for all trials

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2012

Completed
25 days until next milestone

First Submitted

Initial submission to the registry

January 26, 2012

Completed
1 day until next milestone

First Posted

Study publicly available on registry

January 27, 2012

Completed
4.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2016

Completed
Last Updated

July 11, 2016

Status Verified

July 1, 2016

Enrollment Period

4.5 years

First QC Date

January 26, 2012

Last Update Submit

July 7, 2016

Conditions

LeukemiaLymphoma

Keywords

adult acute lymphoblastic leukemiachildhood acute lymphoblastic leukemiaadult T-cell leukemia/lymphoma

Outcome Measures

Primary Outcomes (2)

  • PDLIM2 expression patterns in cancer and control tissues

  • 8-week survival of human T-cell co-cultured with HTLV-1-transformed T-cell lines

Interventions

gene expression analysisGENETIC
laboratory biomarker analysisOTHER

Eligibility Criteria

AgeUp to 120 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients With T-Cell Acute Lymphoblastic Leukemia

DISEASE CHARACTERISTICS: * Specimens (e.g., tissue, blood, and bodily fluids) of various cancer cells and or tissues from de-identified patients such as T-cell acute lymphoblastic leukemia (T-ALL) * Normal control tissue PATIENT CHARACTERISTICS: * Not specified PRIOR CONCURRENT THERAPY: * Not specified

Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.

Sponsors & Collaborators

Biospecimen

Retention: SAMPLES WITH DNA

tissue, blood, and bodily fluids

MeSH Terms

Conditions

LeukemiaLymphomaPrecursor Cell Lymphoblastic Leukemia-LymphomaPrecursor T-Cell Lymphoblastic Leukemia-Lymphoma

Interventions

Gene Expression Profiling

Condition Hierarchy (Ancestors)

Neoplasms by Histologic TypeNeoplasmsHematologic DiseasesHemic and Lymphatic DiseasesLymphoproliferative DisordersLymphatic DiseasesImmunoproliferative DisordersImmune System DiseasesLeukemia, Lymphoid

Intervention Hierarchy (Ancestors)

Genetic TechniquesInvestigative Techniques

Study Officials

  • Gutian Xiao, MD

    University of Pittsburgh

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
RETROSPECTIVE
Sponsor Type
NETWORK
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 26, 2012

First Posted

January 27, 2012

Study Start

January 1, 2012

Primary Completion

July 1, 2016

Last Updated

July 11, 2016

Record last verified: 2016-07